Estimated survival times according to NOTCH1^mut and SF3B1^mut. PFS was defined as the time from first drug administration to disease progression or death, and was censored at the initiation of subsequent treatment without progression. OS was defined as the time from first drug administration to death, and was censored at the time of allo-SCT. (A) Progression-free survival (PFS) of patients with NOTCH1^mut (n = 12; median PFS: 15.47 months) was significantly longer as compared with patients with NOTCH1^WT (n = 82: median: 6.74 months) (P = .025). (B) OS of patients with NOTCH1^mut (n = 12; median OS: not reached) was not significantly different as compared with patients with NOTCH1^WT (n = 82; median OS: 18.3 months) (P = .181). (C) PFS of patients with SF3B1^mut (n = 17; median PFS: 4.76 months) was not significantly different as compared with patients with SF3B1^WT (n = 77; median PFS: 7.72 months) (P = .974). (D) OS of patients with SF3B1^mut (n = 17; median OS: 29.0 months) was not significantly different as compared with patients with SF3B1^WT (n = 77; median OS: 17.1 months) (P = .243). WT, wild-type.